In8bio Inc Market Cap ($9.36 Million)
Market Cap & Net Worth: In8bio Inc (INAB)
In8bio Inc market cap. In8bio Inc (NASDAQ:INAB) has a market capitalization of $9.36 Million ($9.36 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27106 globally and #5634 in its home market, demonstrating a -1.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying In8bio Inc's stock price $0.95 by its total outstanding shares 9858383 (9.86 Million). Also see INAB operating cash flow for how efficiently the company converts equity into cash flow.
In8bio Inc Market Cap History (2021–2026)
In8bio Inc market cap history from 2021 to 2026. Data shows change from $43.28 Million to $9.36 Million (-36.05% CAGR). Check INAB stock price for real-time trading data and today's change.
Index Memberships
In8bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #762 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2479 of 3165 |
Weight: In8bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
In8bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how In8bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore In8bio Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of INAB by Market Capitalization
Companies near In8bio Inc in the global market cap rankings as of November 4, 2026. Also see how large is In8bio Inc's balance sheet for a full breakdown of the balance sheet.
Key companies related to In8bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of In8bio Inc (2021–2026)
Market capitalization of In8bio Inc from 2021 to today. Between 2021 and today, In8bio Inc's market cap moved from $43.28 Million to $ 9.36 Million, with a yearly change of -36.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.36 Million | -59.41% |
| 2025 | $23.07 Million | +809.80% |
| 2024 | $2.54 Million | -81.36% |
| 2023 | $13.60 Million | -40.26% |
| 2022 | $22.77 Million | -47.38% |
| 2021 | $43.28 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of In8bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.36 Million USD |
| MoneyControl | $9.36 Million USD |
| MarketWatch | $9.36 Million USD |
| marketcap.company | $9.36 Million USD |
| Reuters | $9.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell… Read more